复合人体溶性血栓模块素剂量与血症诱导的散布性血管内凝血患者的死亡率之间的相关性
Tatsuro Kobayashi1, Ryusei Mikami2, Mineji Hayakawa3
1Department of Pharmacy, Isesaki Municipal Hospital, Isesaki, Japan.
Thrombosis journal
|October 22, 2025
概括
减少复合人溶性血栓模块素 (rhTM) 用于败血症引起的散布性血管内凝血 (DIC) 的剂量与更糟糕的结果有关. 标准的rhTM剂量策略似乎更有效地改善了败血症引起的DIC患者的存活率.
科学领域:
- 临界护理医学 临界护理医学
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
背景情况:
- 对于因败血症引起的扩散性血管内凝血 (DIC) 的复合人溶性血栓模块素 (rhTM) 的最佳剂量尚不清楚.
- 之前的研究还没有全面评估不同rhTM剂量策略对死亡结果的影响.
研究的目的:
- 调查不同rhTM剂量策略对败血症引起的DIC患者住院死亡率的影响.
- 为了比较标准剂量和减少剂量的rhTM管理之间的结果.
主要方法:
- 对167名被诊断患有败血症的成年患者进行了回顾性,单中心的队列研究,并为DIC (2011-2024) 用rhTM治疗.
- 主要结局:住院死亡率. 二次分析包括日志等级测试和考克斯比例危险分析.
- 使用双重稳定方法来调整混偏差和反向概率权重.
主要成果:
- 标准剂量组 (n=84) 的死亡率为30%,而减少剂量组 (n=83) 的死亡率为42%.
- 标准的rhTM剂量与明显更好的结果相关 (调整后的危险比:0.561;P=0.039).
- 平均rhTM剂量为328U/kg/天,标准剂量组的低度较高.
结论:
- 在败血症引起的DIC中,基于功能的rhTM剂量减少策略与较低的死亡率结果有关.
- 研究结果表明,标准的rhTM剂量可能更有利于改善这种患者群体的存活率.
- 进一步的前性研究是有必要的,以验证这些发现,因为这项研究的回顾性质.
更多相关视频
07:05Visualization of Neutrophil Extracellular Traps in Mesenteric Venules After Mesenteric Ischemia-Reperfusion Injury via Intravital Microscopy
Published on: September 27, 2024
826
13:08Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
19.4K
相关概念视频
Venous Thrombosis III: Interprofessional Care
278
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
278
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.7K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.7K
Therapeutic Drug Monitoring: Affecting Factors
200
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
200
Therapeutic Drug Monitoring: Overview and Classification
306
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
306
